This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Gianni Bonadonna, MD; Milvia Zambetti, MD; Pinuccia Valagussa
Istituto Nazionale Tumori Milan, Italy

JAMA. 1995;274(10):796-797.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—The Table summarizes the comparative adjuvant results reported by the research groups^1-3 quoted in the letter from Dr Michaelson. Although we concur in stating the limits of interseries comparisons, particularly when treatment results are at different follow-up periods, available findings reiterate the efficacy of our sequential drug regimen. We believe that

doxorubicin followed by CMF represents a step forward in the control of occult micrometastases at the expense of minimal important toxicity. However, for clinicians who consider that in any clinical situation only results from prospective trials comparing newer vs older treatments commit them to apply an innovative therapy, we do not exclude the possibility that in the future some cooperative groups will offer the final verdict. . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?